NCTN-Oral Agent Shipment Funding Info Sheet (7/27/2020)
Updated Protocol Deviation Memo & Log (7/10/2020)
CTEP Oral IND Agent Shipments Memo (6/2/2020)
Coming Soon: National Cancer Institute Natural History Study of COVID-19 in Cancer Patients (4/20/2020)
NRG Oncology Leadership Special Message Regarding COVID-19 (4/13/2020)
CIRB Information about COVID-19 (3/27/2020)
CIRB Remote Consent Procedures and Other FAQ’s (4/22/2020)
FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic (7/2/2020)
Guidance for Collection of Adverse Events Related to COVID-19 Infection(3/25/2020)
Additional Guidance Regarding Alternative Procedures for Clinical Trials Supported by the NCI Cancer Therapy Evaluation Program (CTEP) and NCI Community Oncology Research Program (NCORP) Affected by the Spread of the Novel Coronavirus (3/23/2020) NRG Oncology Leadership Special Message Regarding COVID-19 (3/23/2020)
Updated Interim Guidance for Patients on Clinical Trials Sponsored by the NCI Cancer Therapy Evaluation Programs: Shipment of Oral IND Agents to Clinical Trial Subjects (3/23/2020)
NRG Oncology Leadership Special Message Regarding COVID-19 (3/14/2020)
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.